Postoperative death occurred in 2.5 percent of patients in the primary-surgery group and in 0.7 percent of patients in the neoadjuvant-chemotherapy group. Grade three or four 4 hemorrhage happened in 7.4 percent of patients after primary debulking and in 4.1 percent after interval debulking, infection in 8.1 percent and 1.7 percent, respectively, and venous complications in 2.6 percent and 0 percent, respectively. At non-e of the assessment moments were the differences in the QLQ-C30 global health ratings significant. The overall test for cure effect on global health was also not significant. General Survival and Progression-Totally free Survival Overall survival was related in the two groupings in the intention-to-treat analyses , as was progression-free survival . The median overall survival was 29 months in the primary-surgery group and 30 a few months in the neoadjuvant-chemotherapy group, and the median progression-free survival in both combined groups was 12 months.Announced today that it has finished a $32 million Series A preferred stock funding led by Novo Ventures with participation from Alta Companions, RiverVest Venture Partners and the Roche Venture Fund. Peter Moldt , PhD., Partner at Novo Ventures, Robert Alexander , PhD., Director at Alta Companions and John McKearn PhD., Managing Director at RiverVest Venture Partners, will join the Board of Directors. Related StoriesOne World Lab announces collaboration with BenchWise to improve antibody researchCalcitonin-gene related peptide antibody inhibition shows migraine prevention promiseJanssen symptoms license agreement with Alligator Bioscience for immuno-oncology antibody Commented Dr.